Clinical trial / 2009
Chondroitins 4 and 6 sulfate significantly reduced joint space width loss and improved pain faster than placebo in patients with knee osteoarthritis over 2 years.
In an international trial, 622 patients with knee osteoarthritis were randomized to receive 800 mg chondroitins 4 and 6 sulfate (CS) or placebo once daily for 2 years. Intent-to-treat analysis showed a significant reduction in minimum joint space width (JSW) loss in the CS group (-0.07 +/- 0.03 mm) compared to placebo (-0.31 +/- 0.04 mm; P < 0.0001). The proportion of patients with radiographic progression >= 0.25 mm was lower with CS (28% vs. 41%, P < 0.0005; relative risk reduction 33%), and pain improved significantly faster in the CS group (P < 0.01) with no differences in safety.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 622 patients with knee osteoarthritis
- What was measured
- Loss in minimum joint space width (JSW) over 2 years, radiographic progression, pain, and safety
THE PAPER
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial.
Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Arthritis Rheum, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.